LONDON, Aug. 16, 2016 /PRNewswire/ -- Cancer is a leading cause of death worldwide. According to GLOBOCAN 2012, the incidence of cancer is expected to increase from 14 Million in 2012 to approximately 21 Million by 2030. Although conventional therapies, such as chemotherapy and radiotherapy, have been the roots to slow down the progression of tumors, however till date no complete treatment of this disease is available in the market. Furthermore, these conventional therapies have numerous side-effects associated with them, such as nausea, hair loss and abnormal blood cell counts. These limitations and adverse effects of conventional therapies have therefore created a significant need for the treatment of cancer. This led to development of new therapies to curb the prevalence of this disease with minimal side-effects. One such therapy is cancer immunotherapy, particularly T-cell immunotherapy. T-cell immunotherapy has shown great promise in the treatment of patients with late-stage cancer.
According to RNCOS' new research report "T-Cell Immunotherapy for Cancer - Pipeline Analysis", T-cell immunotherapy is one of the most widely researched fields in the recent years. The high potential of T-cell based therapies to cure various types of cancer indications makes it a popular research area. Numerous researches are being performed across the globe to explore the potential of T-cell immunotherapy for the treatment of different therapeutic areas. The rapidly expanding field of T-cell immunotherapy has experienced clinical successes along with some critical issues. T-cell immunotherapy has emerged as one of the innovative and potent arm of the Immunotherapeutics market.
The report provides an in-depth study on the current state of the T-Cell Immunotherapy industry. Currently, there is no commercialized T-cell immunotherapy; however due to high venture capitalist investments and increasing research related activities, this market is slated to witness a precipitous growth in the coming years. The report provides detailed analysis of various other factors affecting the growth of the market.
The report also covers the global as well as regional prevalence of major types of cancer for which T-cell immunotherapy is used. These cancers include leukemia, lymphoma, melanoma, ovarian cancer, and bladder cancer amongst others. This will help the companies to gain knowledge regarding the target population for various immunotherapies globally, and at regional level.
The report also provides detailed pipeline analysis of T-cell immunotherapy. In this context, the study provides a comprehensive overview of various aspects of the clinical trials in the T-cell immunotherapy market, such as phases, geographies, vectors used, therapeutic indications, technology types, and key players. The segment also covers the list of the key ongoing clinical trials along with their clinical phases. According to the research, CAR-T is the most widely used technology by the companies. Moreover, the report also suggests that most of the T-cell immunotherapies are in the research or pre-clinical phase. Limited number of therapies has been able to cross Phase I of the clinical trials.
Several companies and academic institutions are operating in this market with a focus on developing T-cell immunotherapy for 'difficult to treat' cancers. These companies are also receiving various funding, grants, and investment from non-industry participants, and other companies and venture capitalist firms, which are aiding them to develop new products. The report provides details about major venture capitalist investments, government grants, and IPO raised in this market.
Finally, with a view to understanding the competitive landscape, the profiles of key market players have been included in the report to present a complete picture of the global T-cell Immunotherapy market. The profiles of these companies include business overview, financials, product pipeline, and their strength and weakness analysis. Major players operating in the T-cell Immunotherapy market are Adaptimmune Therapeutics plc, Juno Therapeutics, Inc., Kite Pharma, Inc., Novartis International AG, Tessa Therapeutics Pte Ltd., Gradalis, Inc., Immunovative Therapies, Ltd., Lion Biotechnologies, Inc., Atara Biotherapeutics, Inc., Celgene Corporation, Cellular Biomedicine Group, GlaxoSmithKline plc, Immunocore Ltd., Cell Medica, and Inovio Pharmaceuticals, Inc.
Download the full report: https://www.reportbuyer.com/product/4053948/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/t-cell-immunotherapy-for-cancer---pipeline-analysis-300314422.html